Lunai Bioworks has secured its first revenue-generating multi-year contract with the U.S. government to deploy its AI platform for chemical threat assessment, marking a significant step in its national security biodefense strategy. The company also formed the Pathfinder Consortium with top institutions like Harvard and Purdue to enhance its biodefense capabilities. Alongside this, Lunai is advancing its precision neurology pipeline targeting diseases like epilepsy and Alzheimer's using AI-driven methods. Additionally, Lunai has initiated legal action against alleged market manipulation to protect shareholder value. Moving forward, the company aims to expand its biodefense platform and neurology programs while pursuing litigation to address stock price suppression.
Hubbell reported strong Q2 2026 results with revenue of $1.71 billion, exceeding the $1.66 billion consensus and marking a 15% sales increase year-over-year. Earnings per share reached $5.52, beating estimates and rising 12% from last year. The compa...
Logitech International SA is set to report its Q2 2026 earnings on July 28, with analysts forecasting an EPS of about $1.30 and revenue near $1.2 billion, marking a 5% increase year-over-year. The company anticipates improved profitability with a gro...
CRCAM Alpes Provence has published its financial report as of June 30, 2026. The document is accessible on their official website and has been submitted to the French financial regulator, the Autorité des Marchés Financiers. This release ensures tran...
Between July 20 and July 24, 2026, Capgemini executed a buyback of 68,613 of its own shares at an average price of €91.59 per share. This transaction is part of the company's ongoing efforts to manage its capital structure and potentially enhance sha...
Commvault Systems reported strong Q1 2026 results, surpassing earnings per share and revenue estimates with EPS of $1.42 and revenue of $314.13 million. Subscription-based services drove growth, with subscription ARR up 22% to $1.05 billion and SaaS ...
